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Abstract: Copper is a key element affecting blood vessel growth and muscle development. 
However, the ions released from Cu salts are toxic. Given their specific physicochemical 
properties, nanoparticles of Cu (NanoCu) may have different bioactivity and affect the 
development of blood vessel and muscles in a different manner than Cu salts. The 
objective of the study was to evaluate the influence of NanoCu on embryo development 
and angiogenesis at the systemic and molecular level, in experiments using a chick embryo 
model. Fertilized chicken eggs were divided into a control group, and groups injected  
with a placebo, CuSO4 or NanoCu. Embryo development at the whole body level and  
molecular indices using an embryo chorioallantoic membrane model were measured during 
embryogenesis. The present study indicated for the first time that NanoCu have pro-angiogenic 
properties at the systemic level, to a greater degree than CuSO4 salt. The properties of 
NanoCu were confirmed at the molecular level, demonstrating significant effects on mRNA 
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concentration and on mRNA gene expression of all pro-angiogenic and pro-proliferative 
genes measured herein. 
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1. Introduction 
Copper is a key microelement required by animals and humans. Although the content of Cu in the 
human body is only about 100 mg it plays an important and multifunctional role as a cofactor of many 
enzymes [1]. Cu serves as a catalytic and structural cofactor for enzymes that function in energy 
generation (as a component of cytochrome c oxidase (COX), and is involved in iron acquisition, 
oxygen transport, cellular metabolism, peptide hormone maturation, blood clotting, signal transduction 
and a host of other processes [2]. 
Cu is essentially involved in angiogenesis as a stimulator of angiogenesis, vasculogenesis and 
endothelial cell migration [3]. Cu levels were found to locally regulate the growth or regression of new 
blood vessels. Furthermore, Cu affects the expression of structurally diverse but vital angiogenic 
growth factors such as vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF2), 
tumor necrosis factor (TNF)-α and platelet-derived endothelial cell growth factor (PD-ECGF) [4]. 
VEGF is recognized as the key regulator of angiogenesis, and is more efficient than FGF2 in the 
stimulation of differentiation of endothelial cells [5]. Cu is required for the activation of  
hypoxia-inducible factor-1 (HIF-1), a major transcription factor regulating the expression of  
VEGF [6]. As an angiogenic cofactor, Cu is also implicated in new vessel formation by interacting 
with endothelial and smooth muscle cells, leading to cell migration, invasion, proliferation and the 
formation of tubular structures [7]. Cu has also been shown to stimulate angiogenesis in chick embryo 
chorioallantoic membrane (CAM) models [4]. 
Muscle development is determined mainly during embryogenesis, and consequently the final 
number of muscle fibers is accomplished in the prenatal and early post hatch periods [8]. Moreover, 
muscle maturation during embryogenesis is dependent on the development of a vessel network, which 
provides cells with oxygen and nutrients; Cu may interfere indirectly with the molecular status of 
muscle maturation during embryogenesis via effects on myoblast determination protein 1 (MyoD1) 
and paired box protein 7 (Pax7). 
At the nanometer scale (1–100 nm) there are collections of atoms or molecules, the properties of 
which are neither those of the individual constituents nor those of the bulk material. At this scale, 
many atoms are located on the surface of nanoparticles [9]. The unique bioactivity of nanoparticles 
together with their very small size influence the properties and behavior of nanoparticles when 
introduced to an organism, related to transportation, distribution, biochemical activities and molecular 
responses [10]. As an essential element that is present in very small amounts in the body, Cu is 
involved in many different processes, playing a dual role in the organism (also being a pro-cancer 
agent), and may in the form of nanoparticles show different effects. Chen et al. [11] reported that the 
LD50 for Cu nanoparticles (size 23.5 nm), Cu particles (size 17 μm) and ions in mice was 413, >5000 
and 110 mg/kg body weight, respectively. This result classified both nanoparticles and ions as class 3 
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(moderately toxic) agents. Given that nanoparticles seem to be less toxic than ions in standard 
toxicological experiments, they have potential applicability as biological agents, making it important to 
investigate molecular responses to Cu nanoparticles. 
The objective of this study was to evaluate the influence of nanoparticles of copper on angiogenesis at 
the systemic and molecular level in comparison to Cu salt, in experiments using a chick embryo model. 
2. Results 
Chicken embryo development, at day 3, 6, 9, 12, 15, 18 and 20 of incubation, was compared with 
the Hamburger–Hamilton normal stages of chicken embryo development. All embryos developed 
normally and no genetic or other defects were detected. The administration of CuSO4 and NanoCu to 
the chicken embryo by the in ovo method did not influence the weight of the body, heart, liver or 
spleen evaluated at day 20 (Table 1). 
Table 1. Weight of the body and chosen organs, evaluation according to Hamburger–Hamilton 
development stages (HH) and mortality of chick embryo at 20 day, after in ovo treatment 
with CuSO4 and nanoparticles of Cu (NanoCu). 
Indices 
Groups ANOVA 
Control CuSO4 NanoCu SEM p-Value 
Body Weight 49.5 48.67 49.93 3.672 ns 
Liver 1.128 1.001 1.001 0.143 ns 
Spleen 0.028 0.026 0.024 0.0061 ns 
Heart 0.434 0.382 0.420 0.0391 ns 
HH correct correct correct   
Mortality % 8.1 11.2 9.0   
ns = non-significant, p < 0.05. 
Evaluation of the development of the embryos at day 9 showed that the development of blood 
vessels was more intense in the NanoCu group than in the CuSO4 group and much denser than in the 
control group (data not shown). To verify this observation experiments were carried out on the 
induction of angiogenesis. Implants soaked with PBS, CuSO4 or NanoCu were placed on the CAM and 
after 2 days, at day 12 of incubation, the vessel network was observed. Both forms of Cu promoted the 
development of vessels; however, the number of branches and length of vessels was greater in the 
NanoCu group compared to the control and the CuSO4 group (Table 2, Figure 1). 
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Table 2. The number of branches of blood vessels examined on implants (with diameter  
1 cm) incubated on the chick embryo chorioallantoic membrane, after in ovo treatment 
with CuSO4 and nanoparticles of Cu (NanoCu). 
Indices 
Groups ANOVA 
Control CuSO4 NanoCu SEM p-Value 
Number of Branches 7.9 a 12.6 b 17.3 c 0.43 0.000 
Length of vessels mm 7.3 a 11.5 b 13.2 b 0.97 0.000 
a,b,c: within rows, means bearing different superscripts differ significantly at p < 0.05. 
 
Figure 1. Images of implants maintained on the chicken embryo chorioallantoic membrane 
(CAM) for 2 days, soaked with: (1) control (not soaked); (2) control (PBS); (3) CuSO4;  
(4) NanoCu, evaluated at day 12 of incubation. Scale bars, 2000 µm. 
The results concerning VEGF-A, FGF2, PCNA, MyoD1, Pax7 and COX gene expression 
normalized to the β-actin (ACTB) gene at the mRNA level indicated that the experimental treatments 
influenced mRNA synthesis in embryo breast muscle (Table 3). 
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Table 3. The mRNA expression of VEGF-A, FGF2, PCNA, MyoD1, PAX7 and COX genes 
and concentration of DNA and RNA in the samples of pectoral muscles of embryos at day 
18 and day 20, after in ovo treatment with CuSO4 and nanoparticles of Cu (NanoCu). 
Indices 
Groups ANOVA 
Control CuSO4 NanoCu SEM p-Value 
 Day 18 
VEGF-A 11.14 13.84 10.87 1.231 ns 
FGF2 4.12 a,b 2.92 b 5.42 a 0.957 0.012 
PCNA 0.90 0.73 0.68 0.085 ns 
MyoD1 0.37 a 0.78 b 0.57 a,b 0.147 0.014 
COX 4.96 3.15 3.59 0.805 ns 
Pax7 0.59 0.58 0.65 0.075 ns 
DNA 258.7 202.5 249.0 39.18 ns 
RNA 2194.2 2291.0 2391.9 186.6 ns 
RNA/DNA ratio 8.5 11.3 9.6   
 Day 20 
VEGF-A 21.69 a 25.66 a 36.96 b 2.184 0.000 
FGF2 1.30 a 6.72 b 9.00 c 0.952 0.000 
PCNA 0.68 a 0.62 a 2.54 b 0.134 0.000 
MyoD1 1.08 a 3.10 c 1.91 b 0.327 0.000 
COX 16.81 16.20 18.52 2.085 ns 
Pax7 0.62 a 0.21 b 0.25 b 0.269 0.000 
DNA 249.3 289.9 247.8 43.06 ns 
RNA 1182.6 a 1066.3 b 1798.6 c 82.17 0.000 
RNA/DNA ratio 4.7 3.7 7.3   
ns = non-significant; a,b,c: within rows, means bearing different superscripts differ significantly at p < 0.05. 
VEGF-A expression did not differ significantly between embryos treated with CuSO4 and NanoCu 
at day 18 but at day 20, expression tended to be higher in the CuSO4 group and was significantly 
higher in the NanoCu group than in the control group (1.8 times higher). The expression of FGF2 was 
not significantly affected at day 18 in comparison to the control group; however, NanoCu had a 
significantly greater effect than CuSO4. At day 20, FGF2 was upregulated by CuSO4, and to a greater 
extent by NanoCu. FGF2 expression was about five-fold higher in CuSO4 and seven-fold higher in the 
NanoCu group than in the control group. Neither CuSO4 nor NanoCu affected the expression of PCNA 
at day 18, but at day 20, expression was significantly increased by NanoCu treatment. When MyoD1 
was examined at day 18, the level of expression was significantly higher in embryos treated with 
CuSO4 compared to the control group. At day 20, MyoD1 expression was significantly higher in the 
embryos treated with NanoCu and even higher (three-fold higher) in the CuSO4 than in the control 
group. The expression of COX, examined at day 18 and 20, was not affected. Pax7 gene expression 
was not influenced by experimental treatments at day 18; however, at day 20, it was significantly 
reduced in the CuSO4 and NanoCu groups compared to the control group. The DNA and RNA 
concentrations in the breast muscle at day 18 were not affected by the treatments, but at day 20 the 
RNA concentration was lower in the CuSO4 group and substantially higher in the NanoCu group 
compared to the control group. 




The results indicated that copper in the form of salt (CuSO4) as well as in metal form (Cu°), 
introduced into chick embryos by in ovo injection, did not influence embryo growth or development. 
Neither form of Cu was harmful when injected as 300 μL of colloid/salt at a concentration of 50 ppm 
of Cu. These results confirm our earlier findings with chick embryos and growing chicks [12,13]. 
Moreover, our previous studies indicated that neither Cu nanoparticles nor silver or gold nanoparticles 
interfere with the growth and development of embryos when used at levels up to 50 ppm [14–16]. 
CuSO4 is a source of Cu ions whereas nanoparticles of Cu are a source of particles of metal with a 
highly bioactive surface and also a small quantity of Cu ions. Interestingly the amount of ions released 
is strongly dependent on the pH of the environment (compartment of cells), which is also positively 
correlated with the toxicity of Cu nanoparticles. Nevertheless, at pH = 7 the percentage of Cu ions 
originating from nanoparticles was 0.1%–0.3% [17]. The physical form (ions vs. metal) influences the 
majority of Cu bio-properties, hence, the key issue of the present investigation was to indicate 
differences between Cu salt and Cu nanoparticle bioactivities in the process of angiogenesis at the 
systemic and molecular level. 
In our experiment, we observed more intense development of the vessel network (growing outside 
the chicken embryo until day 15) and increased vascularization of implants maintained on CAM after 
CuSO4 treatment in comparison to the control group. In experiments using the rabbit cornea 
vascularization model, the application of CuSO4 provoked neovascularization [18]. It is known that  
Cu is involved in angiogenesis, being a pleiotrophic agent that influences numerous mediators of 
angiogenesis [6,19]. This fundamental mechanism has even been used as a promising anticancer 
treatment [20]. Our observations confirm this phenomenon. 
However, the pro-angiogenic effects observed after NanoCu treatment, which were significantly 
more potent compared to those produced by CuSO4, have never been reported. Thus, the present study 
is the first to indicate that nanoparticles of Cu have pro-angiogenic properties at the systemic level, to a 
greater degree than CuSO4 salt. 
Gene expression at the mRNA level, measured in samples of breast muscle from the chick embryos, 
did not unambiguously support these observations. New vessel growth requires the chronological 
activation of many receptors by numerous ligands, but a critical rate-limiting step in angiogenesis is 
VEGF signaling [21]. Cu is required for the stimulation of hypoxia-inducible factor-1 (HIF-1), the 
most important transcription factor regulating the expression of VEGF [20]. VEGF is also responsible 
for the proper development of the vascular system in skeletal muscles [22], in which gene expression 
was measured in our experiment. Further, VEGF as an endothelial cell mitogen is involved in 
angiogenesis as well as vasculogenesis. In our experiment expression of VEGF-A was not affected by 
either treatment at day 18, or by CuSO4 treatment at day 20, but at day 20 NanoCu treatment almost 
doubled the expression of VEGF-A compared to the control. VEGF-A is regulated by hypoxia, 
oxidative stress, growth factors and cytokines [23,24]. However, during embryogenesis in normal 
physiological conditions, FGF plays a crucial role in VEGF-dependent vasculogenesis. Experiments 
with epicardial cells, which form vascular tubes, indicated that most of the FGF family of proteins, 
including FGF2, regulates the tubulogenic response [25]. Interestingly, FGF effects are VEGF 
dependent, while tubulogenesis induced by VEGF also requires FGF signaling. This interaction 
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between VEGF-A and FGF2 was seen at the level of gene expression at day 20. The highest mRNA 
expression of VEGF-A and FGF2 was observed in the NanoCu treatment, consistent with vessel 
network development in the chicken embryo and CAM implant model. 
At day 18, however, neither VEGF nor FGF2 expression were significantly influenced by Cu 
treatments compared to the control group. Nevertheless, the FGF2 mRNA concentration was higher 
after NanoCu than CuSO4 treatment. The number and migration of endothelial cells was significantly 
increased by FGF2 [26]. FGF2 transmits signals preferentially via tyrosine kinase receptors (FGFR1–4), 
non-tyrosine kinase receptors and also via cell-surface FGFR-interacting proteins [26]. The spectrum 
of the interaction of FGF2 is very wide, and CuSO4 and NanoCu may interfere with the same or only 
partly the same signal pathways. NanoCu as metallic particles may be sequestered in different ways 
than Cu salt, and consequently the signaling properties of the two forms of Cu may differ. It is also 
possible that the activity of FGF2 during embryogenesis, which might be modulated by CuSO4 or 
NanoCu, is time dependent and that biosignaling by the metallic form (NanoCu) occurs over a longer 
period compared to CuSO4 salt. Furthermore, the reason that expression of FGF2 after NanoCu 
treatment was higher compared to the CuSO4 treatment at the end of embryogenesis, may be a more 
efficient transport and different signaling pathways of the metallic form. Hence, it will be crucial to 
investigate the behavior of NanoCu within tissue and cells in future experiments. 
FGF2 activity is observed from early phases of embryogenesis and is highly involved in cell 
proliferation [27,28], and consequently is a strong PCNA inducer [29]. This was reflected in the 
expression of PCNA after NanoCu treatment at day 20. In comparison to CuSO4, NanoCu significantly 
increased PCNA expression—a key marker of cell division. However, this was not observed at day 18, 
pointing to the possibility that NanoCu extend the period of predominance of hyperplasia over 
hypertrophy at the end of embryogenesis. 
To identify further molecular effects on breast muscle development after treatment with different 
forms of copper two other FGF2-dependent genes were examined: MyoD1 and Pax7. MyoD1, unlike 
FGF2, activates mechanisms of skeletal muscle lineage determination and differentiation [30]. 
Myogenic regulatory factors (including MyoD1) in the embryo muscle are markers of cell 
differentiation, inducing the synthesis of myogenin, which leads to the suppression of cell 
proliferation. This process increases at the end of embryogenesis but at the end of embryo 
development the proliferation of muscle cells slows down and almost ceases [31]. In the current study 
treatment with CuSO4 increased MyoD1 expression at day 18 two-fold and at day 20 three-fold in 
comparison to the control. It is possible that CuSO4 might increase cell differentiation by increasing 
the vessel network and transport of oxygen and nutrients to muscle cells. However, NanoCu increased 
the MyoD1 mRNA concentration only at day 20 and to a lower degree in comparison to CuSO4. This 
was also confirmed by the reduced expression of Pax7, which in contrast to the anti-proliferative 
MyoD1, is a marker of proliferation of satellite cells. These differences between CuSO4 and NanoCu 
activity also suggest that the bioactivity of NanoCu might be more prolonged. 
In the light of examination of vessel network development at the systemic level, the present results 
show that NanoCu stimulate angiogenesis more than CuSO4. Moreover, the molecular responses 
demonstrate that NanoCu as well as CuSO4 affect the mRNA expression of genes involved in 
angiogenesis and cell proliferation. This may indicate that the level of Cu stored in the egg is 
insufficient, notably at the end of embryogenesis. Furthermore, NanoCu have a stronger effect on 
Int. J. Mol. Sci. 2015, 16 4845 
 
 
mRNA gene expression than CuSO4, which may point to a different mechanism of signaling, as well 
on more efficient sequestration within muscle cells. 
4. Experimental Section 
4.1. Experimental Design 
Chicken eggs from 37-week-old Ross × Ross 308 hens, obtained from a commercial certificated 
hatchery, were stored in a refrigerator (10 °C) for 1–3 days and then placed in an incubator. The eggs 
were randomly divided into four groups (4 × 100 eggs): no injection (control), injected with phosphate 
buffered saline (PBS) as a placebo, or injected with solutions of CuSO4 (CuSO4) or hydrocolloid of 
nanoparticles of copper (NanoCu). At day 1 of incubation, the eggs were weighed (58 ± 1.28 g) and  
0.3 mL of experimental fluids was injected under sterile conditions into the air sac, using 27-gauge,  
20-mm needles. Immediately after the injection, the hole was sealed with sterile tape and the eggs were 
placed in an incubator. The eggs were incubated for 18 or 20 days under standard conditions 
(temperature 37.8 °C, humidity 55%, turned once per hour for the first 18 days, and at a temperature of 
37 °C and humidity 60% from day 20). 
At day 3, 6, 9, 12, 15, 18 and 20 of incubation eggs were randomly selected from each group and 
six embryos from each group were dissected and examined. The developmental status of the chick 
embryos was compared with the developmental stages described by [32]. The network of blood vessels 
in the chorioallantoic membrane (CAM) was evaluated at day 9 and day 12. At day 18 six samples of 
the breast muscle were collected in RNAlater® ribonucleic acid (RNA) stabilization solution (Applied 
Biosystems/Ambion, Austin, TX, USA) for mRNA expression analysis. At day 20 the embryos were 
weighed and decapitated, the liver, heart, spleen were weighed and the breast muscles were prepared 
for mRNA expression analysis. 
4.2. Experimental Solutions 
CuSO4 was obtained from Sigma Aldrich, St. Louis, MO, USA and was dissolved in ultra pure 
water to a concentration of 50 ppm of Cu. The hydrocolloid of NanoCu, at a concentration of 50 ppm, 
was purchased from Nano-Tech, Warsaw, Poland and was produced by a non-explosive high voltage 
method from high purity metals (99.9999%) and high purity demineralized water. 
The Zeta potential of hydrocolloids was measured using a Zetasizer Nano-ZS90 (Malvern 
Instruments Ltd., Malvern, UK): the Zeta potential of NanoCu was −28.1 indicating a stable solution. 
The shape and size of NanoCu were visualized using a JEM-2000EX transmission electron microscope 
(TEM: JEOL Ltd., Tokyo, Japan) at 80 kV (Figure 2). The nanoparticles were spherical and rarely 
elliptical, rounded, with no sharp edges. The diameter of nanoparticles was on average 37.3 nm and 
varied from 15 to 70 nm. 




Figure 2. Transmission electron microscopic image of Cu nanoparticles. 
4.3. Gene Expression at the mRNA Level 
Gene expression at the mRNA level was measured using the quantitative polymerase chain reaction 
method (qPCR). The tissue dissected from the breast muscle was homogenized in TRIzol® Reagent 
(Life Technologies, Naerun, Denmark), and total RNA was extracted according to the manufacturer’s 
instructions. The RNA samples were purified using the SV Total RNA Isolation System (Promega 
Corporation, Madison, WI, USA) and quantified using a NanoDrop ND 1000 spectrophotometer 
(Thermo Fisher Scientific, Waltham, MA, USA). Using reverse transcriptase with oligo (dT) 
(Promega) and random primers (TAG Copenhagen A/S, Copenhagen, Denmark), 2 mg of total RNA 
was reverse transcribed, after which real-time PCR was performed with complementary DNA and 
gene-specific primer pairs (TAG, Copenhagen A/S, Copenhagen, Denmark) mixed with LightCycler® 480 
SYBR Green I Master mix (Roche Applied Science, Penzberg, Germany) in a LightCycler® 480 real-time 
PCR system (Roche Applied Science, Penzberg, Germany). The following primers were used:  
FGF2 (forward: GGCACTGAAATGTGCAACAG, reverse: TCCAGGTCCAGTTTTTGGTC),  
VEGF-A (forward: TGAGGGCCTAGAATGTGTCC, reverse: TCTTTTGACCCTTCCCCTTT), 
PCNA (forward: TGCACGCATTTGTAGAGACC, reverse: AGTCAGCTGGACTGGCTCAT), 
MyoD1 (forward: CGGCGGCTCAGCAAGGTCAAC, reverse: CGGCCCGCTGTACTCCATCATG), 
COX (forward: AGGATTCTATTTCACAGCCCTACAAG, reverse: AGACGCTGTCAGCGATTGAGA),  
Pax7 (forward: CCAGTAGAGACAGGCCAAGC, reverse: GGAGTTGGGAAGGAGTAGGG) and 
ACTB (forward: GTCCACCTTCCAGCAGATGT, reverse: ATAAAGCCATGCCAATCTCG).  
For each complementary DNA, the reaction was performed in triplicate. For analyses, relative 
quantification was conducted using ACTB as the housekeeping gene. 
4.4. Angiogenesis Assay 
Angiogenesis (state of development of the vascular network) was evaluated using the chick CAM 
implantation method according to [33,34]. The CAM method could be performed till day 12 of 
incubation because only in this period vessels grow outside the embryo body. Eggs (3 groups × 20 eggs) 
were incubated as described above. On the 3rd day of incubation a 1 cm2 window in the shell was 
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opened and 3 mL of albumen was removed. The window was sealed with sterile aluminum foil and the 
eggs were placed back in the incubator. At day 9 of incubation the windows were opened and sterilized 
filter paper rings, loaded with experimental solutions (CuSO4 or NanoCu) or PBS as a placebo were 
placed over the developing CAM. The implants were pre-treated with 3 mg/mL of hydrocortisone 
sodium succinate (Sigma, St. Louis, MO, USA) and air dried under sterile conditions. The 
concentration of Cu in CuSO4 and NanoCu was 50 ppm. The windows were then resealed, and the 
eggs were incubated for a further 48 h. At day 12 of incubation, the implants were removed from the 
eggs [34] and the morphology of blood vessel formation around the implants was observed using a 
stereomicroscope under 12.5-fold magnification (SZX10, CellD software version 3.1, Olympus 
Corporation, Tokyo, Japan). Photos were analyzed using CellSens Dimension Desktop version 1.3 
(Olympus Corporation). The vessel network (length of vessels and number of branches) present on the 
implants was evaluated according to [34]. 
4.5. Statistical Methods 
Data was normally distributed and the results were analyzed by analysis of variance computed with 
the least squares method using statistical software SPSS 19.0 PL for Windows (SPSS Inc., Chicago, 
IL, USA), at a significance level of p ≤ 0.05. 
5. Conclusions 
We demonstrated that in ovo administration of Cu as CuSO4 salt or as NanoCu at a concentration of 
50 ppm had no negative effects on embryo development. Both treatments increased vascularization of 
implants maintained on CAM, but the pro-angiogenic effects of NanoCu were more potent compared 
to those produced by CuSO4. The properties of NanoCu were confirmed at the molecular level, 
demonstrating significant effects on mRNA concentration and on mRNA gene expression of all  
pro-angiogenic and pro-proliferative genes measured herein. 
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